Hypertensive nephropathy laboratory findings
Jump to navigation
Jump to search
Hypertensive nephropathy Microchapters |
Differentiating Hypertensive Nephropathy from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hypertensive nephropathy laboratory findings On the Web |
American Roentgen Ray Society Images of Hypertensive nephropathy laboratory findings |
Risk calculators and risk factors for Hypertensive nephropathy laboratory findings |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nasrin Nikravangolsefid, MD-MPH [2]
overview
An elevated level of urinary albumin is a helpful diagnostic test for hypertensive nephropathy.
Laboratory Findings
- Blood tests
- High levels of creatinine, BUN
- Anemia: low Hb and hematocrit
- Hyperlipidemia
- Elevated serum levels of β2-microglobulin and transforming growth factor-β (TGF-β) have been recently found to predict the hypertensive nephropathy. [1]
- Urinary analysis
- High protein levels
- May range from microalbuminuria (< 300 mg/ dl) to overt proteinuria (> 300 mg/ dl)
- Urinary albumin to creatinine ratio may be increased.
- microscopic haematuria
- Presence of podocyte proteins in the urine precede proteinuria, so it can be used as an early investigation. But, laboratory test for detecting podocytuia is not widely available. [2]
- Increased mRNA levels of podocin and nephrin in the urine is another early diagnostic test, which shows glomerular damage and developing hypertensive nephropathy. [2]
- High protein levels
References
- ↑ Cao, Junjie; Hou, Rui; Lu, Jingqian; Zhang, Kongyan; Zhao, Cui; Jiang, Haisen; Feng, Yumei; Wang, Yiwei (2019). "The predictive value of β2‑MG and TGF‑β for elderly hypertensive nephropathy". Experimental and Therapeutic Medicine. doi:10.3892/etm.2019.7278. ISSN 1792-0981.
- ↑ 2.0 2.1 Seccia, Teresa M.; Caroccia, Brasilina; Calò, Lorenzo A. (2017). "Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms". Journal of Hypertension. 35 (2): 205–212. doi:10.1097/HJH.0000000000001170. ISSN 0263-6352.